Merck Signs an Exclusive License and Research Collaboration Agreement with Aqilion for Small Molecule Inhibitors of TAK1 Protein
Shots:
- Aqilion to receive up front of $10.70M & is eligible to receive development and commercialization milestones of ~$1.0174B along with royalties on global net sales. The collaboration focuses to develop differentiated TAK1 therapeutics in a broad range of autoimmune and inflammatory disease indications, incl. neurological diseases
- Under the terms of agreement, Aqilion will be responsible for the design and synthesis of novel small molecule TAK1 inhibitors while Merck will be responsible for preclinical pharmacology and biology studies
- The collaboration builds on Aqilion's extensive experience with Merck's industry-leading expertise in drug discovery and development to bring novel effective treatment
Ref: PRNewswire | Image: Merck
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
